Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, Flow cytometry, etc. |
| Sample | bladder cancer tissues, cell lines (T24, 5637) |
| Expression Pattern | down-regulated |
| Function Description | MEG3 overexpression sensitized BC cells to the chemotherapy drug cisplatin (DDP).MEG3 and p53 could stimulate the expression of each other in BC cells, indicating a potential positive feedback loop of MEG3 and p53.Our data showed that the BC cells overexpressing MEG3 displayed weaker migration and invasion ability than the control cells. |
| Pubmed ID | 29940769 |
| Year | 2018 |
| Title | Up-regulation of LncRNA MEG3 inhibits cell migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |